Bioreactors Market Size By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Technology (Wave-Induced Motion SUB, Stirred SUB, Single-Use Bubble Column),

Bioreactors Market Size By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Technology (Wave-Induced Motion SUB, Stirred SUB, Single-Use Bubble Column), By End-Use (R&D Organizations, Biopharma Manufacturers, CMOs), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, The Netherlands, Denmark, China, Japan, India Australia, South Korea, Singapore, Brazil, Mexico, South Africa, UAE), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025

Bioreactors Market will exceed USD 2.2 billion by 2025; as per a new research report.

Growing biopharmaceutical and biologics industry and technological advancements in bioreactors, coupled with growing demand for orphan drugs and personalized medicines are the major driving factors for the global bioreactors market growth during the forecast period. The growth of biopharmaceutical industry can be attributed to the rising prevalence of chronic disease, increasing aging population, and increased investment in technological advances; especially in the personalized and targeted therapies. Moreover, biological drugs are more effective in comparison to traditional treatments leading to their increasing popularity.

Growing biopharmaceutical industry and use of bioreactors for large-scale production of biopharmaceutical products have generated the need for suppliers to provide excellent product quality, strong change management, and assurance of supply coupled with business continuity. The bioreactor manufacturers strive to develop quality designs and seek consistent performance by partnering with material and component suppliers as well as research scientists for technical know-how. The reliability of the value chain for bioreactors depends upon partnerships and agreements with suppliers and complete understanding and control of the bioreactor manufacturing process.

Mammalian cells segment accounted for more than 75% market share in 2018 owing to its wide application in production of therapeutic proteins and viral vaccines. Other cells should witness more than 13.0% growth over the forecast timeframe due to associated benefits of insect cells such as ease of culture, by-product concentration, high tolerance to osmolality, and higher expression levels.

Monoclonal antibodies generated over USD 270.0 million in 2018 owing to its increasing application in treatment of asthma, breast cancers, rheumatoid arthritis, psoriasis, leukemia, chronic gastrointestinal inflammatory disease, and transplant rejection. Other molecules will grow at more than 16.0% with expectations to surpass USD 200.0 million by 2025. Oligonucleotides demand should increase with the growing research in molecular diagnostics field and soaring investments in genomic technologies.

Wave-induced motion market held more than 50% of industry revenue in 2018 due to its extensive use in modern biotechnological processes. Stirred SUBs will witness more than 17.0% CAGR owing to its huge demand in the biopharmaceutical industry. The ability to reduce scale-up risks and maintain clean environment throughout the production process should stimulate industry growth.

Europe dominated the global bioreactors market and was valued at around USD 284.0 million in the year 2018 owing to the presence of leading industry players and increasing healthcare expenditure in this region. Favorable regulatory policies for biopharmaceutical approval and technological innovation in bioprocess equipment will propel business growth.

The major industry players in the bioreactors market are Sartorius, GE Healthcare, Thermo Fisher Scientific, Eppendorf, and Merck Millipore. Major strategies adopted by the players in the market include new product launch, acquisition strategy, expansion strategy, agreements, and collaborations, among others. For instance, In June 2016, Sartorius acquired Intellicyt, a firm specialized in cell screening. This acquisition expanded Sartorious’ product lab portfolio and strengthened its offering for biopharma customers and helped in penetrating the market.